All Life Sciences & Technology News
Top stories summarized by our editors
6/19/2018

An untranched round of Series B funding raised $32.5 million for WindMIL Therapeutics. The company has an ongoing midstage trial of unmodified marrow-infiltrating lymphocytes for the treatment of multiple myeloma.

Full Story:
BioCentury
More Summaries:
multiple myeloma
6/19/2018

Stealth BioTherapeutics intends to use the $100 million raised from two convertible note rounds to launch a Phase IIb study of elamipretide for the treatment of patients with intermediate dry age-related macular degeneration. The drug is also in a Phase II/III trial for Barth syndrome and Leber's hereditary optic neuropathy and a late-stage study for mitochondrial myopathy.

Full Story:
BioCentury
6/19/2018

Bayer is confident that Monsanto's biotech weed killer Roundup cannot be proven to cause cancer. Bayer's newly acquired Monsanto is facing a test case involving a pest manager with non-Hodgkin lymphoma that he thinks is linked to Roundup, which is based on glyphosate.

More Summaries:
Monsanto, Bayer, Lymphoma, glyphosate
6/19/2018

Allergan tapped actress Shay Mitchell to quiz women on birth control facts such as what time of day they should take their pill and whether all birth control pills have the same formulation. "In conversations with my friends and family, it is constantly made clear to me that people are not speaking about birth control as much as they should be," said Mitchell, who added that when discussions happen, "the dialogue is riddled with misconceptions."

Full Story:
FiercePharma
More Summaries:
Shay Mitchell
6/19/2018

Red Cross asked more than two dozen of its media outlet partners to change their logos for World Blood Donor Day last week in an effort to highlight the low number of blood donations globally. Some partners, such as The Dodo, dropped letters corresponding with blood types, with the "o"s slowly falling away after visitors landed on the site, while others highlighted letters in red, such as AOL, which included a red blood drop in its logo.

More Summaries:
Red Cross, Red Cross, AOL
6/18/2018

House lawmakers passed 38 bills aimed at combating the opioid-abuse epidemic last week, including measures that would give the National Institutes of Health more authority to study nonaddictive painkillers and prevent opioid smuggling through international mail. The House expects to pass this week at least another 19 opioid measures and a legislative vehicle that would wrap in all of the opioid bills passed by the chamber, with the goal of sending the bills to the Senate this summer.

6/18/2018

A sensor has been developed by Chinese scientists to enable the detection of prostate cancer circulating tumor cells by capturing them on frosted glass microscope slides. The slides have tiny depressions that grow silica nanowires on their surfaces, which act like Velcro to trap and tangle up CTCs, with the possibility of detecting as few as 10 tumor cells in a milliliter of blood, researchers reported in ACS Applied Materials & Interfaces.

6/18/2018

Bluebird bio reported at the European Hematology Association meeting last week that changes to its gene therapy candidate LentiGlobin boosted the experimental therapy's efficacy based on results from its early-stage study. The trial consists of four patients with sickle cell disease, who are now producing a median of 39% of healthy hemoglobin in their blood after receiving the treatment.

Full Story:
Xconomy
More Summaries:
Bluebird Bio
6/18/2018

Regenxbio's RGX-111, being developed as a treatment for patients with mucopolysaccharidosis type 1, received fast-track status from the FDA.

Full Story:
eMPR
More Summaries:
mucopolysaccharidosis, FDA, Regenxbio
6/18/2018

Teva Pharmaceutical Industries will halt a late-stage study evaluating the safety and efficacy of TEV-48125, or fremanezumab, in patients with chronic cluster headaches. The company said the trial is unlikely to meet the primary endpoint of reducing the number of headaches.